Introduction: However, compensatory mutations have been reported to partially restore the viral replication capacity, including rtL80V/I, rtL82M, rtV173L and rtV207I, mostly in the RT region of pol.
Frequency of Hepatitis B Virus Resistance Mutations in Women Using Tenofovir Gel as Pre-Exposure Prophylaxis.
Result: No mutations known to cause tenofovir resistance (L180M, A181I/V, A194T, M204V/I, V214A, Q215S, N236T) or lamuvudine (3TC) resistance (L80V/I, I169T, V173L, L180M, A181T, T184S, M204V/I/S, Q215S) were observed.
Molecular Epidemiology of Hepatitis B Virus in Turkish Cypriot.
PMID: 31880889
2019
Polish journal of microbiology
Discussion: When analyzed in greater details, rtM204I, rtI233V, rtL80I, and rtL180M mutations were not detected before, and these mutations, particularly rtL80I and rtL180M, restore the activity of viral polymerase to near wild type levels, which helps to promote the replication of mutants.
Naturally occurring hepatitis B virus reverse transcriptase mutations related to potential antiviral drug resistance and liver disease progression.
PMID: 29713126
2018
World journal of gastroenterology
Abstract: Eight mutations in Conclusion: Eight mutations in RT region, rtL80I, rtD134N, rtN139K/T/H, rtY141F, rtM204I/V, rtF221Y, rtI224V, and rtM309K were significantly associated with progression of HCC in treatment-naive patients.
Table: L80I/V
Analysis of HBV basal core promoter/precore gene variability in patients with HBV drug resistance and HIV co-infection in Northwest Ethiopia.
Result: Overall, the most prevalent RAM was rtM204V/I in both treatment experienced and treatment naive individuals, and occurring either alone or in combination with other polymorphisms rtL80I/V, rtV173L, rtL180M, rtA181S, rtT184S, rtA200V and/or rtS202S (Fig 3); mutations among individuals with and without exposure to HBV therapy are listed in S4 Table and S5 Table, respectively).
Discovery of the Novel Entecavir-Resistant Hepatitis B Virus Reverse Transcriptase A181C Substitution From an Integrated Genotypic Analysis.
Result: One patient (Pt14) harboring rtL80I+rtM204I achieved undetectable HBV DNA subsequent to virologic breakthrough.
Result: The rtL80I substitution has been reported to be a compensatory substitution selected by LVD treatment to enhance the replication efficiency of the LVDr substitution rtM204I without affecting LV
Result: The phenotypic and virologic outcomes data suggested that rtL80I+-rtN131G+rtQ316H did not impact ETVr development.
Table: L80I
High Prevalence of HBV Lamivudine-Resistant Mutations in HBV/HIV Co-Infected Patients on Antiretroviral Therapy in the Area with the Highest Prevalence of HIV/HBV Co-Infection in China.
Discussion: In our study, twenty (95.2%) of the 21 patients had at least one mutation that may confer clinical resistance to both telbivudine (rtM204V/I) and 3TC (rt180M + rtM204V/I, rtV173L + rtL180M + rtM204V/I, and rtL80I + rtM204I).
Abstract: RESULTS: In 34 out of 161 study subjects (21.1%) HBV drug resistance mutations (DRMs) were detected with a frequency of 3.1% rtL80F/I, 0.6% rtA181V, 1.2% rtT184S, 6.2% rtV173L, 10.6% rtL180M, 10.6% rtM204V/I and 8.1% rtI233V.
HBV mutation literature information.
PMID: 
2019
Antiviral research
Browser Board
Co-occurred Entities
Filtrator
ViMRT